Covid-19 roundup: Pfiz­er says Xel­janz re­duced death and lung fail­ure in hos­pi­tal­ized Covid-19 pa­tients; US halts dis­tri­b­u­tion of Eli Lil­ly’s mAb com­bo to Rhode Is­land due to vari­ants

In ad­di­tion to its ul­tra-ef­fec­tive mR­NA vac­cine, Pfiz­er be­lieves it could have an­oth­er weapon to fight the Covid-19 pan­dem­ic.

The com­pa­ny re­port­ed on Wednes­day that its rheuma­toid arthri­tis block­buster Xel­janz sig­nif­i­cant­ly low­ered the in­ci­dence of death or res­pi­ra­to­ry fail­ure in hos­pi­tal­ized pa­tients with Covid-19 pneu­mo­nia in Brazil.

“To ef­fec­tive­ly com­bat the COVID-19 pan­dem­ic, there re­mains a crit­i­cal need for mul­ti­ple ther­a­peu­tic op­tions to treat pa­tients who have con­tract­ed the virus,” Tamas Kon­cz, CMO of Pfiz­er In­flam­ma­tion & Im­munol­o­gy, said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.